louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04901026: Satisfaction With an In-house Developed Nasal Foreign Body Removal Manikin
Official title: Satisfaction With an In-house Developed Nasal Foreign Body Removal Manikin: A Randomized-controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Satisfaction
Consumer Satisfaction
Keywords: manikin
nasal foreign body
Lead sponsor: Prince of Songkla University
Sponsor class: OTHER
First posted: 2021-05-25
Enrollment: 37
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: OTHER

Brief summary: To overcome the issues regarding training in real persons, using a simulated manikin instead of an actual patient or simulated patient is another option with consideration to the training able to be held at any time periods and no issues about minor or serious complications needed to be concerned with. The aim of this study is to devise a low-cost manikin with a specific design to serve all possible needs of end users but still keep its function as necessary for training.


Eligibility criteria: Inclusion Criteria:

* Physicians who hold a MD degree

Exclusion Criteria:

* Not want to complete questionnaires
* No experience in a nasal foreign body removal

Primary outcomes:
measure: Satisfaction Scores
timeFrame: 1 day for each manikin
Secondary outcomes:
Other outcomes:
Locations:
city: Hat Yai
country: Thailand
facility: Faculty of Medicine, Prince of Songkla University
state: Songkhla
Study officials:
References:
Clinical trial NCT01257126: Efficacy of Diclofenac Potassium vs Nimesulide in the Treatment of Fever and Pain in Children With Upper Respiratory Tract Infection
Official title: Efficacy of Diclofenac Potassium Versus Nimesulide in the Treatment of Fever and Pain in Children Aged 3 to 7 Years With Community Acquired, Non-complicated, Upper Respiratory Tract Infection
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE4
Conditions: Upper Respiratory Tract Infections
Keywords: Upper respiratory tract infections
diclofenac potassium
nimesulide
fever
pain
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2010-12-09
Enrollment: 0
Sex: ALL
Minimum age (years): 3
Maximum age (years): 7
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a local, phase IV, open-label, randomized, head to head study of children aged 3 to 7 years. The objective of the study is to compare the efficacy of a single dose of both diclofenac potassium and nimesulide in the reduction of fever and pain secondary to upper respiratory tract infection.


Eligibility criteria: Inclusion Criteria:

* Children who present community acquired, non-complicated, upper respiratory tract infection: rhino-sinusitis, pharyngitis, tonsillitis, ear infection or the combination of these.
* Child must present axillary temperature ≥ 37.5°C.

Exclusion Criteria:

* Prior history of allergic reaction to the components of the study medication.
* Use of any NSAID or pharmacologic agent in the 24 hours prior to visit 1.
* Subjects who, in the opinion of the investigator, have developed, or are at risk of developing, a complicated infection and are not suitable subjects for the purposes of the study.

Other protocol-defined inclusion/exclusion criteria may apply

Primary outcomes:
measure: Reduction of fever as measured by axillary temperature
timeFrame: 120 minutes
Secondary outcomes:
measure: Reduction of pain as measured by visual analog scale
timeFrame: 120 minutes
Other outcomes:
Locations:
Study officials:
affiliation: Novartis Pharmaceuticals
name: Novartis Pharmaceuticals
role: STUDY_DIRECTOR
References:
Clinical trial NCT01934426: Identification of Admission High Risk Elderly
Official title: Identification of Admission High Risk Elderly From Multiple Cohorts: a Pilot Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pneumonia
Urinary Tract Infection
Stroke
Keywords: Admission High Risk Elderly
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2013-09-04
Enrollment: 760
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study populations include as below; A.Retrospective cohort group B.Perspective cohort group

Brief summary: Objective: The study aim to establish high risk admission model and readmission model for elderly in Taiwan.

Method: Investigators compare the clinical, epidemiological, and socioeconomic characteristics of admitted patients during 1 August,2011 to 31 July,2012. All patients will follow up to end of study to identify 14 days readmission and 30 days readmission to geriatic ward.

Expected Outcomes: (1) To compare the prediction value of derivation cohort and validation cohort. (2) To identify high risk indicators of admission and readmission for elderly. (3) To determine the risk factors in admission elderly association with quality indicators.


Eligibility criteria: Inclusion Criteria:

1. Patients with age 65 year old above
2. Patients admission to geriatric ward

Exclusion Criteria:

1. Patients with unstable vital sign
2. Patients or dependants reject to sign inform consent.

Primary outcomes:
measure: Determine percentages of high risk in elderly 14 days readmission to geriatric ward
timeFrame: 1-year
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
affiliation: National Taiwan University Hospital
name: Ding-Cheng Chan, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00000226: Alternate-Day Buprenorphine Administration. Phase VII - 8
Official title: Alternate-Day Buprenorphine Administration. Phase VII
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Opioid-Related Disorders
Lead sponsor: National Institute on Drug Abuse (NIDA)
Sponsor class: NIH
Collaborators: name: University of Vermont
First posted: 1999-09-21
Enrollment: 0
Sex: ALL
Minimum age (years): 21
Maximum age (years): 48
Standard ages: ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine if four times a subjects daily maintenance dose will hold for 96 hours without changes in agonist and antagonist effects under open dosing conditions.


Eligibility criteria: Please contact site for information.

Primary outcomes:
measure: Drug use
measure: Opioid withdrawal
measure: Opioid agonist effects
measure: Pupil diameter
Secondary outcomes:
Other outcomes:
Locations:
city: Burlington
country: United States
facility: Treatment Research Center
state: Vermont
Study officials:
affiliation: University of Vermont
name: Warren Bickel, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Patry, Bicket, Tzanis, Badger (in preparation). Every fourth day dosing with buprenorphine (2) A comparison of four different dosing schedules under open and choice procedures.. Patry, Bickel, Tzanis, Badger (in preparation). Every fourth day dosing with buprenorphine (2) A comparison of four different dosing schedules under open and choice procedures.
Clinical trial NCT02915926: Occupational Performance Coaching in Mothers of Children With Cerebral Palsy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cerebral Palsy
Lead sponsor: University of Social Welfare and Rehabilitation Science
Sponsor class: OTHER
First posted: 2016-09-27
Enrollment: 30
Sex: FEMALE
Minimum age (years): 25
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A single-blind Randomized Controlled Trial will be used to test the efficacy of the OPC on self-efficacy and occupational performance with mothers of children with cerebral palsy. Canadian Occupational Performance Measurement and Sherer general self-efficacy scale will be employed to data collection. The sample size was determined for each group of 15 people. The participants conveniently and according to inclusion and exclusion criteria will be randomized into the groups. Participants in the intervention group will be participated in 10 sessions of OPC. At the end the questionnaires will be completed by both groups.


Eligibility criteria: Inclusion Criteria:

mothers: being literate 25 to 25 caring nobody disabled other than her child children: 5 to 12 cerebral palsy

Exclusion Criteria:

children: others problems that affect on communication

Primary outcomes:
measure: Canadian Occupational Performance Measure
timeFrame: 10 weeks
Secondary outcomes:
measure: Sherer general self-efficacy
timeFrame: 10 weeks
Other outcomes:
Locations:
city: Tehran
country: Iran, Islamic Republic of
facility: Mina Ahmadi Kahjoogh
Study officials:
References:
Clinical trial NCT03474926: Prognostic Value of Lymph Node Dissection in Patients With Transitional Cell Carcinoma of the Upper Urinary Tract
Official title: Prospective Randomized Phase II Trial: Comparing the Prognostic Value of Routine Lymphadenectomy Versus Lymphadenectomy Only for Lymph Nodes Enlargement Found in Preoperative Imaging or During Surgery Undergoing Nephroureterectomy in Patients With Primary Upper Tract Urothelial Carcinoma
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Lymph Node Dissection
Keywords: urothelial cancer
nephroureterectomy
Upper urinary tract
Lead sponsor: RenJi Hospital
Sponsor class: OTHER
Collaborators: name: Peking University First Hospital
First posted: 2018-03-23
Enrollment: 504
Sex: ALL
Minimum age (years): 15
Maximum age (years): 80
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Recent studies showed the therapeutic benefit of lymphadenectomy in advanced stage urothelial carcinoma of the upper urinary tract, but there is still a lack of prospective studies. Thus, the current guideline recommends lymph node dissection for invasive upper tract urothelial carcinoma (UTUC) on the basis of insufficient evidence. Also, the preoperative judgment of muscle invasive pathological stage T 2+,or N+ is difficult from preoperative imaging. In the investigators' clinical practice, the surgeons performed dissection of regional lymph nodes only in patients with enlargement of lymph nodes found in preoperative imaging or during surgery. The aim of this multi-institutional study was to examine the role of lymphadenectomy in urothelial carcinoma of the upper urinary tract.


Eligibility criteria: Inclusion Criteria:

* clinically diagnosed with upper tract urothelial carcinoma
* have no distant metastasis
* have an Eastern Cooperative Oncology Group (ECOG) score 0 to 2
* expected to receive radical nephroureterectomy

Exclusion Criteria:

* a prior history of bladder cancer
* administration of neoadjuvant chemotherapy
* deny to receive long term follow-up
* patients with contralateral UTUCs
* patients with synchronous muscle invasive bladder cancer

Primary outcomes:
measure: Disease free survival
timeFrame: 36 month
Secondary outcomes:
measure: Cancer specific survival
timeFrame: 36 month
measure: Overall survival
timeFrame: 36 month
measure: The recurrence rate of bladder cancer in the 36 month following nephroureterectomy
timeFrame: 36 month
measure: Perioperative complications rate
timeFrame: 90 day
Other outcomes:
Locations:
city: Beijin
country: China
facility: Peking University First Hospital
state: Beijin
city: Shanghai
country: China
facility: Renji Hospital, School of Medicine, Shanghai Jiao Tong University
state: Shanghai
Study officials:
affiliation: Renji Hospital, School of Medicine, Shanghai Jiao Tong University
name: Wei Xue, M.D
role: PRINCIPAL_INVESTIGATOR
affiliation: Peking University First Hospital
name: Liqun Zhou, M.D
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00759226: Chemotherapeutic Trial With Gemcitabine, Cisplatin, 5-FU and Folinic Acid in Esophageal Cancer
Official title: An Open Labeled Phase 2 Study of Gemcitabine in Combination With Cisplatin, 5-FU (24h CI) and Folinic Acid in Patients With Inoperable Esophageal Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Esophageal Cancer
Keywords: esophageal cancer
Gemcitabine
Cisplatin
5-FU
Folinic Acid
inoperable esophageal cancer
Lead sponsor: CONKO-Studiengruppe
Sponsor class: OTHER
Collaborators: name: Eli Lilly and Company
name: medac GmbH
First posted: 2008-09-25
Enrollment: 92
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This multicenter open labeled phase 2 trial examines the efficacy of a combination of Gemcitabine 1000 mg/m2 (30 min), Cisplatin 30 mg/m2 (90 min), Folinic Acid 200 mg/m2 (30 min) and 5-FU 750 mg/m2 (24h CI) all given day 1,8 q D22 in patients with inoperable esophageal cancer. The combination was considered to be suitable for further evaluation with a freedom of progression rate (PR+CR+SD) of more than 60% and not be be of further interest with a rate of less than 40%. Given an alpha error of 5% and an beta error of 10% at least 66 evaluable patients were needed based on a 2-Stage Simon design with a first evaluation after 25 evaluable patients.


Eligibility criteria: Inclusion Criteria:

* Age\>=18
* Histologically proven inoperable esophageal cancer
* Karnofsky Performance status \>=60%
* Estimated life expectancy of \> 12 weeks
* Measurable disease
* No other oncologic therapy
* Measurable disease
* Adequate bone marrow function
* Geographic proximity and compliance
* Informed consent
* Negative pregnancy test and adequate contraception

Exclusion Criteria:

* Insufficient hepatic or renal function
* Elevated serum calcium
* Pregnancy/breast feeding
* Active infection
* Other malignancies
* Systemic tumour complications requiring emergency interventions

Primary outcomes:
measure: Primary endpoint rate of freedom of progression (PR+CR+SD).
timeFrame: Max. 8 cycles of therapy
Secondary outcomes:
measure: Secondary endpoint median survival, progression free survival and toxicity.
timeFrame: 3 years
Other outcomes:
Locations:
city: Berlin
country: Germany
facility: Charite Universitätsmedizin Berlin
Study officials:
affiliation: Charite Universitätsmedizin Berlin
name: Hanno Riess, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06360757: Clinical Evaluation of the NeuMoDx SARS-CoV-2 Assay (COVID-19)
Official title: Multi-Center Clinical Performance Evaluation of the NeuMoDx SARS-CoV-2 Assay on the NeuMoDx Molecular Systems
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: SARS-CoV-2 Acute Respiratory Disease
Lead sponsor: QIAGEN Gaithersburg, Inc
Sponsor class: INDUSTRY
First posted: 2024-04-11
Enrollment: 503
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Symptomatic subjects suspected of COVID-19

Brief summary: A multicenter study, using prospectively collected, fresh (Category I) and frozen (Category II), residual/leftover nasopharyngeal (NP) swab in UTM/UVT specimens obtained from symptomatic individuals suspected of COVID-19 infection. This study will evaluate the NeuMoDx SARS-CoV-2 Assay's clinical performance on the NeuMoDx 288 and NeuMoDx 96 Molecular Systems.


Eligibility criteria: Inclusion Criteria:

1. Any de-identified NP swab specimen in transport medium from a symptomatic individual suspected of COVID-19 at the time of collection.
2. NP swab specimens obtained using a flexible mini-tip flocked swab and collected into 3mL Copan UTM \[Cat. No. 305C\] or BD UVT \[Cat. No. 220531\].
3. Prospective specimens, fresh (Category I) shall be tested within:

   1. (4) hours when held at room temperature, or
   2. (3) days when held at (2 to 8°C), with cold storage starting within (4) hours of collection.
4. Minimum volume of ≥ 2mL.

Exclusion Criteria:

1. Required information unable to be obtained from the associated medical chart.
2. Specimens that remained on-board the NeuMoDx System for \> (8) hours prior to processing.

Primary outcomes:
measure: Sensitivity as compared to the comparator method
timeFrame: Through study completion estimated 9 months
Secondary outcomes:
measure: Specificity
timeFrame: Through study completion estimated 9 months
Other outcomes:
Locations:
city: Manchester
country: United Kingdom
facility: QIAGEN Gaithersburg, Inc
Study officials:
References:
Clinical trial NCT01401426: Randomized Prospective Trial: Single Port Laparoscopic Vertical Sleeve Gastrectomy Versus Conventional Five Port Laparoscopic Vertical Sleeve Gastrectomy Surgery
Official title: Randomized Prospective Trial: Single Port Laparoscopic Vertical Sleeve Gastrectomy Versus Conventional Five Port Laparoscopic Vertical Sleeve Gastrectomy Surgery
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Obesity
Nutrition Disorders
Body Weight
Keywords: overweight
Obesity, Morbid
Lead sponsor: St. Luke's-Roosevelt Hospital Center
Sponsor class: OTHER
First posted: 2011-07-25
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Vertical Sleeve Gastrectomy has been shown to significantly reduce weight and has been approved as a treatment of morbid obesity. The standard laparoscopic operation requires five small incisions for the introduction of instruments and the band into the patient's abdomen. The investigators have developed a technique for performing this operation through a single incision at the belly button. This study compares this method to the conventional 5-incision approach.


Eligibility criteria: Inclusion Criteria:

* BMI \>40
* ASA I or II

Exclusion Criteria:

* Comorbid cardiac, pulmonary, renal, hepatic disease
* Bleeding disorder
* Previous gastric/esophageal surgery

Primary outcomes:
measure: Weight Loss
timeFrame: 1 month and 1 year
Secondary outcomes:
measure: Quality of life
timeFrame: 1 week and 3 months
measure: Peri-Operative Complications
timeFrame: 1 month
Other outcomes:
Locations:
city: New York
country: United States
facility: St. Luke's Roosevelt Hospital Center
state: New York
Study officials:
References:
Clinical trial NCT05548257: Mortality and Related Risk Factors After Hip Arthroplasty
Official title: Mortality and Related Risk Factors After Hip Arthroplasty, a Retrospective Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Fracture of Neck of Femur (Hip)
Femoral Head Necrosis
Dislocation of Hip Joint
Dysplasia of Hip Joint
Lead sponsor: RenJi Hospital
Sponsor class: OTHER
First posted: 2022-09-21
Enrollment: 900
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All adult patients undergoing hip arthroplasty in Renji Hospital.

Brief summary: The patients who underwent hip arthroplasty in our hospital from January 2017 to December 2020 were reviewed. The perioperative data were collected, and then the mortality was calculated and the risk factors were analyzed.


Eligibility criteria: Inclusion Criteria:

* All patients undergoing hip arthroplasty in Renji Hospital during 2017.1-2020.12

Exclusion Criteria:

* Patients who did not undergo surgery after admission Age \< 18 years Patients undergoing the second operation

Primary outcomes:
measure: Risk factors of mortality one year after operation
timeFrame: From about even days before operation to 12 months after operation
Secondary outcomes:
measure: Risk factors of lower activities of daily living score at 12 months after operation
timeFrame: From about even days before operation to 12 months after operation
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01420757: Laparoscopic Versus Open Incisional Hernia Repair
Official title: Laparoscopic Versus Open Incisional Hernia Repair : A Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Postoperative Pain
Complications
Recurrence
Keywords: operation time
length of hospital stay
Lead sponsor: Erasmus Medical Center
Sponsor class: OTHER
First posted: 2011-08-22
Enrollment: 206
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Primary closure of incisional hernia without the use of a mesh shows recurrence rates of up to 54%. If a mesh is used, the defect can be closed tension-free. Using this method, recurrence rates have been reduced to 8-21%. Laparoscopic correction of incisional hernia is a relatively new technique in which the mesh is positioned intraperitoneally. Research has shown that this procedure is technical feasible and may have benefits for the patients.

The ongoing debate about the merits of endoscopic versus open incisional hernia repair prompts the need for a level 1 randomized controlled trial.


Eligibility criteria: Inclusion Criteria:

* hernia diameter between 3 and 15 cm
* location at the ventral abdominal wall at least 5cm from costae and inguinal area
* indication for elective repair
* age of 18 years or older
* written informed consent.

Exclusion Criteria:

* contraindication for pneumoperitoneum
* an absolute contraindication for general anesthesia
* history of open abdomen treatment
* patients participating in other trials

Primary outcomes:
measure: Postoperative pain
timeFrame: 4 weeks
Secondary outcomes:
measure: Postoperative analgesics use
timeFrame: 1 week
measure: complications
timeFrame: 4 weeks
measure: operation time
timeFrame: 1 day
measure: length of hospital stay
timeFrame: 4 weeks
measure: recurrence
timeFrame: 5 years
measure: mortality
timeFrame: 5 years
Other outcomes:
Locations:
Study officials:
affiliation: Erasmus Medical Center
name: J.F. Lange, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: